SG11201500145TA - Crystalline forms of dihydropyrimidine derivatives - Google Patents

Crystalline forms of dihydropyrimidine derivatives

Info

Publication number
SG11201500145TA
SG11201500145TA SG11201500145TA SG11201500145TA SG11201500145TA SG 11201500145T A SG11201500145T A SG 11201500145TA SG 11201500145T A SG11201500145T A SG 11201500145TA SG 11201500145T A SG11201500145T A SG 11201500145TA SG 11201500145T A SG11201500145T A SG 11201500145TA
Authority
SG
Singapore
Prior art keywords
crystalline forms
dihydropyrimidine derivatives
dihydropyrimidine
derivatives
crystalline
Prior art date
Application number
SG11201500145TA
Other languages
English (en)
Inventor
Yingjun Zhang
Qingyun Ren
Xinchang Liu
Chaolei Wang
Tianming Wang
Siegfried Goldmann
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of SG11201500145TA publication Critical patent/SG11201500145TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201500145TA 2012-09-27 2013-09-27 Crystalline forms of dihydropyrimidine derivatives SG11201500145TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210369019 2012-09-27
CN201310117076 2013-04-04
PCT/CN2013/084383 WO2014048355A1 (en) 2012-09-27 2013-09-27 Crystalline forms of dihydropyrimidine derivatives

Publications (1)

Publication Number Publication Date
SG11201500145TA true SG11201500145TA (en) 2015-02-27

Family

ID=50355923

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201500145TA SG11201500145TA (en) 2012-09-27 2013-09-27 Crystalline forms of dihydropyrimidine derivatives

Country Status (20)

Country Link
US (1) US9403814B2 (enExample)
EP (1) EP2900664B1 (enExample)
JP (1) JP6310923B2 (enExample)
KR (1) KR20150060610A (enExample)
CN (3) CN103694234A (enExample)
AU (1) AU2013324779B2 (enExample)
BR (1) BR112015002979B8 (enExample)
CA (1) CA2881260C (enExample)
DK (1) DK2900664T3 (enExample)
ES (1) ES2660642T3 (enExample)
HU (1) HUE037285T2 (enExample)
MX (1) MX362829B (enExample)
MY (1) MY171497A (enExample)
PL (1) PL2900664T3 (enExample)
PT (1) PT2900664T (enExample)
RU (1) RU2646599C2 (enExample)
SG (1) SG11201500145TA (enExample)
TW (1) TWI561520B (enExample)
WO (1) WO2014048355A1 (enExample)
ZA (1) ZA201500290B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2892893B2 (en) 2012-09-10 2019-10-16 F.Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
ES2794639T3 (es) * 2015-11-04 2020-11-18 Qilu Pharmaceutical Co Ltd Forma cristalina, método de preparación y compuesto intermedio de compuesto con anillo dihidropirido
CN107400125B (zh) * 2016-05-19 2020-02-11 广东东阳光药业有限公司 二氢嘧啶衍生物的晶型、盐和复合物及其在药物中的应用
CN107722109B (zh) * 2016-08-11 2020-12-18 广东东阳光药业有限公司 作为丙型肝炎病毒抑制剂的晶型
US9856232B1 (en) * 2017-06-20 2018-01-02 King Saud University Dihydropyrimidinone derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR043880A1 (es) 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
WO2008154819A1 (fr) * 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution carbéthoxy
CN101328170B (zh) 2007-06-18 2011-09-14 张中能 一种氟苯基-取代噻唑二氢嘧啶
AU2008265397C1 (en) * 2007-06-18 2013-08-29 Sunshine Lake Pharma Co., Ltd. Bromo-phenyl substituted thiazolyl dihydropyrimidines
WO2008154820A1 (fr) 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution carbéthoxy
WO2010069147A1 (zh) * 2008-12-17 2010-06-24 张中能 二氢嘧啶类化合物、其组合物及其应用
CN101744823B (zh) * 2008-12-17 2013-06-19 广东东阳光药业有限公司 一种二氢嘧啶类化合物的固体分散体及其药用制剂

Also Published As

Publication number Publication date
BR112015002979A2 (pt) 2017-07-04
RU2646599C2 (ru) 2018-03-06
ZA201500290B (en) 2016-10-26
EP2900664A4 (en) 2016-03-09
MY171497A (en) 2019-10-15
CA2881260A1 (en) 2014-04-03
PT2900664T (pt) 2018-03-02
EP2900664B1 (en) 2017-12-13
KR20150060610A (ko) 2015-06-03
TWI561520B (en) 2016-12-11
ES2660642T3 (es) 2018-03-23
CN104945394B (zh) 2017-12-05
EP2900664A1 (en) 2015-08-05
BR112015002979B8 (pt) 2022-03-03
JP2015531354A (ja) 2015-11-02
CN103724339A (zh) 2014-04-16
MX2015004115A (es) 2016-01-20
US9403814B2 (en) 2016-08-02
AU2013324779A1 (en) 2015-02-05
TW201412732A (zh) 2014-04-01
CA2881260C (en) 2020-10-27
DK2900664T3 (en) 2018-02-05
JP6310923B2 (ja) 2018-04-11
RU2015114085A (ru) 2016-11-20
CN103724339B (zh) 2015-10-14
HUE037285T2 (hu) 2018-08-28
WO2014048355A1 (en) 2014-04-03
BR112015002979B1 (pt) 2020-12-22
CN103694234A (zh) 2014-04-02
HK1207081A1 (en) 2016-01-22
CN104945394A (zh) 2015-09-30
PL2900664T3 (pl) 2018-06-29
MX362829B (es) 2019-02-14
AU2013324779B2 (en) 2015-10-08
US20150239877A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
HUE047354T2 (hu) Ivacaftor deuterizált származékai
PL2709986T3 (pl) Deuterowane pochodne iwakaftoru
HUE036774T2 (hu) Benzonitril-származékok mint kináz inhibitorok
IL230976A0 (en) Crystalline forms of cvezitaxel
PT2912041T (pt) Inibidores de bace
SG11201406860SA (en) Quinazolinedione derivative
GB201501016D0 (en) Preparation of 18F-fluciclovine
IL237458A0 (en) crystalline compounds
ZA201500290B (en) Crystalline forms of dihydropyrimidine derivatives
IL237862A0 (en) Methods to reduce the formation of scale
EP2680843A4 (en) DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS
SG11201503051QA (en) Formulations of pyrimidinedione derivative compounds
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
ZA201502350B (en) Solid form of hihydro-pyrido-oxazine derivative
IL230977A (en) A crystalline form of relapaldib
PT2709584T (pt) Utilização sensorial dos derivados de 6-ciclopentilideno-hexano
IL237824B (en) Crystalline polymorphic form of ulipristal acetate
SI2928896T1 (sl) Trdna oblika derivata dihidro-pirido-oksazina